Gain Therapeutics, Inc. (GANX)
| Market Cap | 21.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -21.14M |
| Shares Out | 18.05M |
| EPS (ttm) | -1.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 266,307 |
| Open | 1.200 |
| Previous Close | 1.120 |
| Day's Range | 1.120 - 1.200 |
| 52-Week Range | 1.110 - 5.330 |
| Beta | 0.48 |
| Analysts | Strong Buy |
| Price Target | 8.25 (+590.38%) |
| Earnings Date | Aug 8, 2024 |
About GANX
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It has various small molecule drug ... [Read more]
Financial Performance
In 2023, GANX's revenue was $55,180, a decrease of -60.62% compared to the previous year's $140,108. Losses were -$22.27 million, 26.6% more than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for GANX stock is "Strong Buy." The 12-month stock price forecast is $8.25, which is an increase of 590.38% from the latest price.
News
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
Mr. Mack is the Company's Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nas...
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson's disease
Data demonstrates improvement in cognitive function in GBA1 Parkinson's disease model in addition to reversal of motor function deficits Data demonstrates improvement in cognitive function in GBA1 Par...
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
BETHESDA, Md., June 25, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of (i) 7,116,547 shares...
Gain Therapeutics Announces Proposed Public Offering
BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced that it is proposing to offer and sell, subject to market conditions, ...
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
New data demonstrating improvement of cognitive performance after treatment with GT-02287 in preclinical model of GBA1 Parkinson's disease New data demonstrating improvement of cognitive performance a...
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
BETHESDA, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the n...
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease
BETHESDA, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
BETHESDA, Md., April 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
BETHESDA, Md., March 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...
Gain Therapeutics to Present at Public Ventures Discovery Day
Gain Therapeutics' Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb Te...
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson's Disease
Data support the ability of GT-02287 to prevent several steps in the disease cascade resulting from GCase misfolding and dysfunction Data support the ability of GT-02287 to prevent several steps in th...
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease
BETHESDA, Md., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insight
Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co., will be held on Thursday, February 22, 2024 at 11:00 am EST Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co....
UPDATE - Gain Therapeutics' GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson's Disease
Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm Data presented at 20th WORLDSym...
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
Presentation will highlight new data of GT-02287 in preclinical models of Parkinson's disease Presentation will highlight new data of GT-02287 in preclinical models of Parkinson's disease
Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model
Compounds significantly restored β-Gal function and reduced intracellular toxic substrates in model of GM1 gangliosidosis
Gain Therapeutics to Participate in AI Driven Drug Discovery Summit
BETHESDA, Md., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of alloste...
Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option
BETHESDA, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the closing of an underwritten public offering of 2,545,000 shares of ...
Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants
BETHESDA, Md., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of 2,213,044 shares of ...
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
Phase 1 clinical study of GT-02287 initiated; dosing escalation on schedule Phase 1 clinical study of GT-02287 initiated; dosing escalation on schedule
Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease
First small molecule allosteric binder discovered with Gain's computational drug discovery platform enters clinical development First small molecule allosteric binder discovered with Gain's computatio...
Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023
BETHESDA, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allost...